Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment

Molecular Therapy

Volumn 19, Issue 4, 2011, Pages 751-759

  Zhang, Ling ^a   Kerkar, Sid P ^a   Yu, Zhiya ^a   Zheng, Zhili ^a   Yang, Shicheng ^a   Restifo, Nicholas P ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MELANOMA ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN TARGETING; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

MURINAE;

EID: 79953325686     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.313     Document Type: Article

References (50)

1. Kobayashi, M, Fitz, L, Ryan, M, Hewick, RM, Clark, SC, Chan, S et al. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170: 827-845. (Pubitemid 19226667)
2. Gubler, U, Chua, AO, Schoenhaut, DS, Dwyer, CM, McComas, W, Motyka, R et al. (1991). Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88: 4143-4147. (Pubitemid 21914495)
3. Gately, MK (1993). Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest 11: 500-506. (Pubitemid 23225924)
4. Mehrotra, PT, Wu, D, Crim, JA, Mostowski, HS and Siegel, JP (1993). Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 151: 2444-2452. (Pubitemid 23264497)
5. Manetti, R, Parronchi, P, Giudizi, MG, Piccinni, MP, Maggi, E, Trinchieri, G et al. (1993). Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4- producing Th cells. J Exp Med 177: 1199-1204. (Pubitemid 23097410)
6. Kennedy, MK, Picha, KS, Shanebeck, KD, Anderson, DM and Grabstein, KH (1994). Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol 24: 2271-2278. (Pubitemid 24303065)
7. Rosenzweig, SD and Holland, SM (2005). Defects in the interferon-and interleukin-12 pathways. Immunol Rev 203: 38-47.
8. Brunda, MJ, Luistro, L, Warrier, RR, Wright, RB, Hubbard, BR, Murphy, M et al. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230. (Pubitemid 23277355)
9. Tahara, H, Zitvogel, L, Storkus, WJ, Robbins, PD and Lotze, MT (1996). Murine models of cancer cytokine gene therapy using interleukin-12. Ann N Y Acad Sci 795: 275-283. (Pubitemid 27029576)
10. Colombo, MP, Vagliani, M, Spreafico, F, Parenza, M, Chiodoni, C, Melani, C et al. (1996). Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56: 2531-2534. (Pubitemid 26170689)
11. Cavallo, F, Di Carlo, E, Butera, M, Verrua, R, Colombo, MP, Musiani, P et al. (1999). Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 59: 414-421. (Pubitemid 29048877)
12. Cohen, J (1995). IL-12 deaths: explanation and a puzzle. Science 270: 908.
13. Leonard, JP, Sherman, ML, Fisher, GL, Buchanan, LJ, Larsen, G, Atkins, MB et al. (1997). Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-production. Blood 90: 2541-2548. (Pubitemid 27413462)
14. Del Vecchio, M, Bajetta, E, Canova, S, Lotze, MT, Wesa, A, Parmiani, G et al. (2007). Interleukin-12: biological properties and clinical application. Clin Cancer Res 13: 4677-4685. (Pubitemid 47294773)
15. Mahvi, DM, Henry, MB, Albertini, MR, Weber, S, Meredith, K, Schalch, H et al. (2007). Intratumoral injection of IL-12 plasmid DNA-results of a phase I/IB clinical trial. Cancer Gene Ther 14: 717-723. (Pubitemid 47080365)
16. Kang, WK, Park, C, Yoon, HL, Kim, WS, Yoon, SS, Lee, MH et al. (2001). Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 12: 671-684. (Pubitemid 32506945)
17. Daud, AI, DeConti, RC, Andrews, S, Urbas, P, Riker, AI, Sondak, VK et al. (2008). Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26: 5896-5903.
18. Dudley, ME, Wunderlich, JR, Yang, JC, Sherry, RM, Topalian, SL, Restifo, NP et al. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357. (Pubitemid 46218728)
19. Dudley, ME, Yang, JC, Sherry, R, Hughes, MS, Royal, R, Kammula, U et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
20. Cohen, CJ, Zheng, Z, Bray, R, Zhao, Y, Sherman, LA, Rosenberg, SA et al. (2005). Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol 175: 5799-5808. (Pubitemid 41508064)
21. Hughes, MS, Yu, YY, Dudley, ME, Zheng, Z, Robbins, PF, Li, Y et al. (2005). Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 16: 457-472. (Pubitemid 40647143)
22. Morgan, RA, Dudley, ME, Yu, YY, Zheng, Z, Robbins, PF, Theoret, MR et al. (2003). High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171: 3287-3295. (Pubitemid 37093556)
23. Johnson, LA, Morgan, RA, Dudley, ME, Cassard, L, Yang, JC, Hughes, MS et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
24. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)
25. Lieschke, GJ, Rao, PK, Gately, MK and Mulligan, RC (1997). Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 15: 35-40.
26. Hooijberg, E, Bakker, AQ, Ruizendaal, JJ and Spits, H (2000). NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood 96: 459-466. (Pubitemid 30463363)
27. Karttunen, J, Sanderson, S and Shastri, N (1992). Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 89: 6020-6024.
28. Finkelstein, SE, Heimann, DM, Klebanoff, CA, Antony, PA, Gattinoni, L, Hinrichs, CS et al. (2004). Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol 76: 333-337. (Pubitemid 39006946)
29. Overwijk, WW, Theoret, MR, Finkelstein, SE, Surman, DR, De Jong, LA, Vyth-Dreese, FA et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569-580. (Pubitemid 37040391)
30. Kerkar, SP, Muranski, P, Kaiser, A, Boni, A, Sanchez-Perez, L, Yu, Z et al. (2010). Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 70: 6725-6734.
31. Weiss, JM, Subleski, JJ, Wigginton, JM and Wiltrout, RH (2007). Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7: 1705-1721. (Pubitemid 350157496)
32. Atkins, MB, Robertson, MJ, Gordon, M, Lotze, MT, DeCoste, M, DuBois, JS et al. (1997). Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3: 409-417. (Pubitemid 27158065)
33. Car, BD, Eng, VM, Lipman, JM and Anderson, TD (1999). The toxicology of interleukin-12: a review. Toxicol Pathol 27: 58-63. (Pubitemid 29075746)
34. Coughlin, CM, Wysocka, M, Trinchieri, G and Lee, WM (1997). The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 57: 2460-2467. (Pubitemid 27255907)
35. Gollob, JA, Mier, JW and Atkins, MB (2001). Clinical use of systemic IL-12 therapy. Cancer Chemother Biol Response Modif 19: 353-369.
36. Fan, H, Walters, CS, Dunston, GM and Tackey, R (2002). IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. Cytokine 19: 126-137. (Pubitemid 35216193)
37. Lee, SW, Park, Y, Yoo, JK, Choi, SY and Sung, YC (2003). Inhibition of TCR-induced CD8 T cell death by IL-12: regulation of Fas ligand and cellular FLIP expression and caspase activation by IL-12. J Immunol 170: 2456-2460. (Pubitemid 36245634)
38. Estaquier, J, Idziorek, T, Zou, W, Emilie, D, Farber, CM, Bourez, JM et al. (1995). T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 182: 1759-1767.
39. Wagner, HJ, Bollard, CM, Vigouroux, S, Huls, MH, Anderson, R, Prentice, HG et al. (2004). A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 11: 81-91. (Pubitemid 38141770)
40. Chen, X, Lin, X, Zhao, J, Shi, W, Zhang, H, Wang, Y et al. (2008). A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine geneengineered MSCs. Mol Ther 16: 749-756. (Pubitemid 351426177)
41. Gao, P, Ding, Q, Wu, Z, Jiang, H and Fang, Z (2010). Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 290: 157-166.
42. Elzaouk, L, Moelling, K and Pavlovic, J (2006). Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 15: 865-874. (Pubitemid 44473325)
43. Smith-Garvin, JE, Koretzky, GA and Jordan, MS (2009). T cell activation. Annu Rev Immunol 27: 591-619.
44. Eisenring, M, vom Berg, J, Kristiansen, G, Saller, E and Becher, B (2010). IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 11: 1030-1038.
45. Rosenberg, SA and Dudley, ME (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240.
46. Prieto, PA, Durflinger, KH, Wunderlich, JR, Rosenberg, SA and Dudley, ME (2010). Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J Immunother 33: 547-556.
47. Besser, MJ, Shapira-Frommer, R, Treves, AJ, Zippel, D, Itzhaki, O, Hershkovitz, L et al. (2010). Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16: 2646-2655.
48. Dudley, ME, Gross, CA, Langhan, MM, Garcia, MR, Sherry, RM, Yang, JC et al. (2010). CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16: 6122-6131.
49. Schambach, A, Galla, M, Maetzig, T, Loew, R and Baum, C (2007). Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 15: 1167-1173. (Pubitemid 46813620)
50. Wargo, JA, Robbins, PF, Li, Y, Zhao, Y, El-Gamil, M, Caragacianu, D et al. (2009). Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother 58: 383-394.